There’s a lot of money to be made in British healthcare, just ask Jonathon Milner. The Cambridge scientist retained a 28 per cent stake in his £58m antibody catalogue business when he listed it on London’s junior market in 2005. Thirteen years and an eight-fold share price increase later and Abcam (ABC) is one of Aim’s biggest companies. Mr Milner – who has made regular share sales in the last few years – now owns 10 per cent of the group, a stake that is worth £250m.
To continue reading, register today
to enjoy limited access to the following:
- Daily trading news
- Funds coverage
- Features on big investment themes
- Comprehensive companies coverage
- Economic analysis